v3.26.1
COMMITMENTS AND CONTINGENCIES - Schedule of Contingent Consideration (Details) - Contingent Consideration Liability - Level 3 - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period $ 26,049 $ 69,657
Payment 0 (5,000)
Change in fair value of contingent consideration liabilities (1,293) (162)
Balance, end of period 24,756 64,495
Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 18,100 38,598
Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 6,656 25,897
Arkis    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 6,299 12,968
Payment 0 (5,000)
Change in fair value of contingent consideration liabilities 9 (812)
Balance, end of period 6,308 7,156
Arkis | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 0 3,598
Arkis | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 6,308 3,558
Derma Sciences    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 350 2,686
Payment 0 0
Change in fair value of contingent consideration liabilities (2) 50
Balance, end of period 348 2,736
Derma Sciences | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 0 0
Derma Sciences | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 348 2,736
ACell    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period   3
Payment   0
Change in fair value of contingent consideration liabilities   0
Balance, end of period   3
ACell | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period   0
ACell | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period   3
Surgical Innovation Associates, Inc.    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, beginning of period 19,400 54,000
Payment 0 0
Change in fair value of contingent consideration liabilities (1,300) 600
Balance, end of period 18,100 54,600
Surgical Innovation Associates, Inc. | Short-Term - Accrued expenses and other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period 18,100 35,000
Surgical Innovation Associates, Inc. | Long-Term - Other liabilities    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance, end of period $ 0 $ 19,600